The global antiviral drugs market size stood at USD 36.1 billion in 2018 and is projected to reach USD 44.2 billion by 2026, exhibiting a CAGR of 3.2% over 2019 to 2026. The rise can be attributed to the growing development of novel therapies by several pharmaceutical companies.

Combination Drugs Segment to Register Notable Surge Driven by Growing Launch of New Therapies

On the basis of drug class, the industry is categorized into reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, combination drugs, polymerase inhibitors, and others. Of these, the combination drugs segment is anticipated to record commendable expansion over the forecast period owing to the rising launch of new therapies. Based on region, the market is subdivided into Europe, Asia Pacific, South America, North America, and the Middle East & Africa.

Request Sample PDF:
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/antiviral-drugs-market-102190

Key Industry Development:

June 2021 – Vaxart, Inc., inked a licensing deal with Altesa Biosciences Inc. The agreement is intended at granting Altesa the right to develop and produce Vaxart’s formulation of Vapendavir.

List of Key Players Mentioned in the Report:
• Janssen Pharmaceuticals, Inc.
• Abbvie, Inc.
• Mylan N.V.
• Gilead Sciences
• Novartis AG
• Bristol-Myers Squibb Company
• GlaxoSmithKline
• Merck & Co., Inc.

HIV Segment to Record Substantial Growth Owing to Favorable Reinforcement Policies in Several Countries

Based on disease indication, the market is segmented into influenza, human immunodeficiency virus (HIV), hepatitis, and others. The HIV segment is slated to register lucrative growth over the estimated period. The escalation can be credited to a rise in favorable reimbursement policies and the incidences of HIV infection in many countries.

Report Coverage:

The report provides an in-depth analysis of the key trends that are slated to drive industry expansion over the forthcoming years. It further gives an insight into the significant trends that are poised to impel the business landscape across various regions. The report also gives an account of the critical steps taken by major industry players for strengthening their position in the market.

Drivers and Restraints:

Industry Value to Rise Driven by Growing Burden of HIV Infection
HIV infection is considered as the most common form of viral infection at the global level. Antiviral drugs market growth can be attributed to the improved rate of disease diagnosis on account of biological and demographic data. The demand for specific and targeted treatment regimens is boosted by the escalating burden of this infection.

However, long-acting antiviral drugs have certain disadvantages including implementation challenges, uncertain costing, and complex delivery. These factors are likely to hinder industry expansion to some extent.

About Us: Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

Contact Us: Fortune Business Insights Pvt. Ltd. 9th Floor, Icon Tower, Baner - Mahalunge Road, Baner, Pune-411045, Maharashtra, India. Phone: US :+1 424 253 0390 UK : +44 2071 939123 APAC : +91 744 740 1245 Email: mailto:[email protected]